AMG 386
Another angiogenesis inhibitor with a unique mechanism of action being evaluated for ovarian cancer is AMG 386. This intravenously administered drug targets the angiogenesis-promoting proteins angiopoietin-1 and -2 and their receptor Tie-2¹⁸. A recent phase 2 clinical study showed that adding AMG 386 to paclitaxel chemotherapy improved PFS by almost 3 months compared with placebo¹⁹. AMG 386 is now being evaluated in a randomized, placebo-controlled phase 3 trial called TRINOVA-1 to determine whether adding this agent to chemotherapy improves PFS in women with ovarian cancer that has recurred following chemotherapy²⁰.